Pune, India -- (SBWire) -- 02/20/2018 --Serotonin syndrome is a collection of signs consisting of high frame temperature, agitation, increased reflexes, tremor, sweating, dilated scholars, diarrhoea and so forth. Due to use of serotonergic drugs Severe headaches together with seizures and enormous muscle breakdown may also occur which may additionally result in dying. The 1984, Libby Zion case is an instance of loss of life from serotonin syndrome.
Global Serotonin Syndrome Market is expected to reach $ 400 million by the end of 2023, this market is projected to growing at a CAGR of ~ 2.3 % during 2017-2023.
Serotonin syndrome is typically caused by synergistic effect of two or more serotonergic drugs which generally include selective serotonin reuptake inhibitor (SSRI), serotonin norepinephrine reuptake inhibitor (SNRI), monoamine oxidase inhibitor (MAOI), tricyclic antidepressants (TCAs), amphetamines etc. Other drugs with a high propensity of causing serotonin syndrome are dextromethorphan, buspirone, L-tryptophan, St. John's wort, metoclopramide, ondansetron etc. There is no laboratory test to confirm the diagnosis of serotonin syndrome.
The treatment for serotonin syndrome consists of discontinuing medications contributing to the condition. For serious cases, other treatments for managing associated symptoms may be used. For serious cases with a threat to life gastrointestinal decontamination using activated charcoal is performed. Sedatives such as benzodiazepines are used for agitated patients. High fever is a common symptom of serotonin syndrome which reaches extremely high temperatures greater than forty centigrade. To control hyperthermia cooling measures may be needed. Serotonin antagonist such as cyproheptadine may be needed.
Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/4075 .
The market restraints are the low number of cases and equally low number of fatalities associated with the syndrome with less than 1% cases consuming serotonin syndrome causing drugs developing the diseases. Mild symptoms occur in about 15% of SSRI overdoses.
Key players of Global Serotonin syndrome market:
Key players profiled in the report are
AstraZeneca Plc.
Eli Lilly and Company,
Forest Laboratories Inc.,
GlaxoSmithKline plc.
Johnson & Johnson Merck & Co. Inc.,
Pfizer Inc.
Sanofi S.A.,
Ciron Drugs & Pharmaceuticals Pvt. Ltd.
Regional analysis
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global serotonin syndrome diagnosis and treatment.
Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/4075 .
Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
…Continued
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Serotonin Syndrome Market Size Forecast Till 2023; by Drug Treatment and End User
Serotonin syndrome market information: by drug treatment (serotonin antagonists, supportive care (Muscle relaxants, sedatives, anti-hyperthermics, antihypertensive, others)